Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP’s acceptability is unknown. We measured acceptability of SP among clinic-based providers (Senegal only) and community health workers. This open-label observational study was conducted in clinics in three districts in Senegal and community-based services in two districts in Uganda. Providers administered SP to clients seeking reinjection of DMPA IM. We conducted in-depth interviews with 86 providers (52 in Senegal, 34 in Uganda) to assess their experiences providing SP to clients.
Institutional Author(s): FHI 360, Centre de Formation et de Recherche en Santé de la Reproduction (CEFOREP), Senegal Ministry of Health and Social Action, Uganda Ministry of Health
Individual Author(s): Holly M Burke, Monique P. Mueller, Catherine Packer, Brian Perry, Leonard Bufumbo, Daouda Mbengue, Bocar Mamadou Daff, Anthony K Mbonye
Publication date: January, 2014